Health Condition 1: I509- Heart failure, unspecified
Conditions
Interventions
Intervention1: Sacubitril and Valsartan: 200mg BD, Oral for minimum 6 months
Control Intervention1: Telmisartan: 40mg OD, Oral for minimum 6 months
Sponsors
Dr Kunwar Shailen Dev Singh Guleria
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient of CHF with decreased ejection fraction 2. Adult patients of either sex, consenting for study 3. If no HF hospitalizations in prior year: BNP greater than or equal to 150 pg/mL 4. If a HF hospitalization in prior year: BNP greater than or equal to 100 pg/mL
Exclusion criteria
Exclusion criteria: 1. Unwilling patient. 2. Pregnant females. 3. Estimated glomerular filteration rate less than 30ml/min/1.73m2 4. Serum potassium greater than 5.2mmol/L 5. Symptomatic hypotensive patients 6. SBP less than 100mmHg at screening or less than 95mmHg at randomization 7.Patient with known history of angioedema 8. Patient on drugs that might interact with ARNI/ARBs 9. Patient with structural (valvular) heart disease. 10.Unacceptable side effects with ACE-inhibitors or ARBs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum BNP levelsTimepoint: After three months and six months of enrollment | — |
Secondary
| Measure | Time frame |
|---|---|
| EchocardiogramTimepoint: After three months and six months of enrollment | — |
Countries
India
Contacts
Public ContactDr Atal Sood
Dr Rajendra Prasad Govt. Medical College Kangra at Tanda
Outcome results
None listed